<DOC>
	<DOCNO>NCT00156611</DOCNO>
	<brief_summary>The Rio Study randomize , double blind German- Swiss- Austria multi-centre trial efficacy safety ReoPro together interventional recanalization TASC D lesion SFA popliteal artery .</brief_summary>
	<brief_title>Rio Trial - ReoPro Peripheral Arterial Intervention Improve Clinical Outcome Patients With Peripheral Arterial Disease</brief_title>
	<detailed_description>Purpose : The RIO trial design test efficacy GP IIb/IIIa blockade subacute reocclusions patient interventional recanalization chronic occlusion superficial femoral popliteal artery . Methods : A total 420 patient randomly assign ReoPro placebo . Patients eligible randomisation occlusion longer 5 cm . Doppler ultrasound follow-up 30 day , 6 , 12 month .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<criteria>Patients history peripheral artery disease superficial femoral popliteal artery occlusion , mandate PTA stent administration first treatment modality . The history peripheral artery occlusion least 6 week , target vessel occlusion 5 centimeter length . Age 18 90 year Acute limb ischemia Subacute ischemia require thrombolysis first treatment modality Active bleeding know bleeding diathesis Known severe hepatic renal disorder ( liver cirrhosis , stage B , C serum creatinine &gt; 2.5 mg % ) Hyperthyreosis Diabetes mellitus treat metformin Known heparin induce thrombocytopenia ( HIT , type 2 ) Female sex childbearing potential Major surgery trauma past 6 week History stroke within previous 2 year , stroke residual neurological deficit , CNS abnormality ( e.g. , intracranial neoplasm , arteriovenous malformation , aneurysm ) Gastrointestinal genitourinary bleed clinical significance within previous 6 week Administration oral anticoagulant within previous 7 day unless prothrombin time &lt; 1.2 time control ( international normalize ratio [ INR ] &lt; 1.4 ) , ongoing treatment oral anticoagulant History bleed diathesis platelet count &lt; 100,000/mm3 Arteriovenous malformation aneurysms Severe uncontrolled hypertension ( treat sys . BP &gt; 200 mm Hg , diast . BP &gt; 100 mm Hg ) Hypertensive diabetic retinopathy Vasculitis Known autoimmune disorder Patient aspirin intolerance Contraindication know allergic reaction abciximab murine protein Coexistent condition associate limited life expectancy ( e.g. , advanced cancer , endstage congestive heart failure ) Participation another clinical research study involve evaluation another investigational drug device within 7 day prior enrollment Patient previously receive GP IIb/IIIa antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>peripheral vascular disease</keyword>
	<keyword>intervention</keyword>
	<keyword>restenosis</keyword>
	<keyword>Age 18 year</keyword>
</DOC>